Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer

This multicenter phase II study first investigated the efficacy and safety of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) when given every 3 weeks to patients with unresectable or recurrent gastric cancer who had received a prior round of fluoropyrimidine‐containing chemotherapy. Patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2014-07, Vol.105 (7), p.812-817
Hauptverfasser:	Sasaki, Yasutsuna, Nishina, Tomohiro, Yasui, Hirofumi, Goto, Masahiro, Muro, Kei, Tsuji, Akihito, Koizumi, Wasaburo, Toh, Yasushi, Hara, Takuo, Miyata, Yoshinori
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Albumin Albumins - adverse effects Albumins - therapeutic use Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Blood Breast cancer Cancer therapies Chemotherapy Disease control Disease-Free Survival Drug dosages Female Gastric cancer Humans Kaplan-Meier Estimate Leukopenia Leukopenia - chemically induced Lymphopenia Male Metastasis Middle Aged nab‐paclitaxel Nanoparticles Neoplasm Recurrence, Local - drug therapy Neutropenia Neutropenia - chemically induced Original Paclitaxel Paclitaxel - adverse effects Paclitaxel - therapeutic use Peripheral neuropathy Pharmaceuticals phase II second‐line chemotherapy Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Survival Treatment Outcome triweekly
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!